Werewolf Therapeutics Inc (HOWL) Stock Price, Quote & News

Company Profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 952 0555

Website: werewolftx.com

Address:

200 Talcott Ave, 2nd Floor, Watertown, United States

longshot45 May. 12 at 7:26 PM

$HOWL Why cant Luke and Ansbert just sell their positions to funds in a large block vs the daily drip? They should be smart enough to realize that once they announce plans to sell, all potential buyers move to the sidelines to wait for a better price. Better for those fools to just negotiate behind closed doors and place 1M shares somewhere and boom theyre done. Ugh I cant wait until they are gone

0 · Reply

BiotechValues May. 12 at 2:06 PM

$HOWL to me this suggests they have another announcement coming in the near-term, or why not just give cash guidance with the 10q update?

2 · Reply

longshot45 May. 12 at 1:52 PM

$HOWL Vanguard new major buyer here as Luke and Ansbert continue their dumping. Was wondering who was helping to absorb their destructive actions

0 · Reply

BiotechValues May. 9 at 3:28 PM

$HOWL IMO their most valuable asset is their INDUCER T-Cell engager platform/programs. This is why they pivoted in Dec to these programs. They saw the upside potential in doing so. I'm pretty optimistic that someone will want to develop these assets given how hot the TCE space has been:

1 · Reply

BiotechValues May. 9 at 2:59 PM

$HOWL bought nearly 500k shares yesterday. Company is now prime for a reverse merger with RA Capital the lead shareholder and Piper still active. Balance sheet is cleaned up with debt gone and lease terminated. I would expect them to monetize their assets/platforms still, similar to what happened with CBIO (sold portfolio for $60M). Interesting few months ahead, and if they execute more sales, lots of potential upside imo...

2 · Reply

longshot45 May. 7 at 10:31 PM

$HOWL $JAZZ I’m a little confised why Jazz didn’t buy werewolf lock stock and barrel here. Just buying JZP899 for 21M + 2 is a steal, but why not take the whole company for like 75M and get the entire pipeline as well as the 489M tax loss Werewolf has on the books? That alone is worth 125M + in tax savings.

2 · Reply

longshot45 May. 7 at 6:08 PM

$HOWL MPM stop monkeying around and Just break .62 already. All this hundreth of a penny BS is such a waste of time for no more than a buck difference. Cant wait for Luke and Ansberth to be gone

2 · Reply

OfficialStocktwitsUser May. 6 at 2:43 AM

$HOWL RSI: 26.92, MACD: -0.0413 Vol: 0.10, MA20: 0.84, MA50: 0.80 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

GregK13 May. 5 at 11:30 PM

$HOWL schedule 13 D form just filed who’s investing in the company?

1 · Reply

zawojak May. 5 at 6:48 AM

$HOWL why is Luke disposing his shares ?

1 · Reply

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

2026-03-27T11:16:02.000Z - 6 weeks ago

Werewolf Therapeutics hires Piper Sandler to assist in strategic evaluation

2026-03-27T11:15:46.000Z - 6 weeks ago

Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c)

2026-03-27T11:10:27.000Z - 6 weeks ago

Werewolf Therapeutics to explore range of strategic alternatives

Mar 27, 2026, 7:00 AM EDT - 6 weeks ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

2026-02-25T00:40:12.000Z - 2 months ago

Werewolf Therapeutics to explore strategic alternatives

2026-02-24T21:51:46.000Z - 2 months ago

Werewolf Therapeutics trading resumes

2026-02-24T21:10:20.000Z - 2 months ago

Werewolf Therapeutics trading halted, news pending

Feb 24, 2026, 4:09 PM EST - 2 months ago

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

2026-02-13T21:30:19.000Z - 3 months ago

Werewolf Therapeutics announces 64% workforce reduction

2025-12-19T15:35:48.000Z - 5 months ago

Citizens downgrades Werewolf Therapeutics on need for capital

2025-12-19T15:30:17.000Z - 5 months ago

Werewolf Therapeutics downgraded to Market Perform from Outperform at Citizens

2025-12-19T14:35:19.000Z - 5 months ago

Wedbush downgrades Werewolf Therapeutics to Neutral on challenging path

2025-12-19T14:30:52.000Z - 5 months ago

Werewolf Therapeutics downgraded to Neutral from Outperform at Wedbush

2025-12-19T12:55:46.000Z - 5 months ago

Werewolf Therapeutics price target lowered to $4 from $10 at H.C. Wainwright

2025-12-18T13:20:39.000Z - 5 months ago

Werewolf Therapeutics provides pipeline update, review of INDUKINE data

2025-12-18T13:20:21.000Z - 5 months ago

Werewolf Therapeutics announces 2025 priorities

Dec 18, 2025, 8:00 AM EST - 5 months ago

Werewolf Therapeutics Announces Pipeline and Business Updates

2025-11-18T14:43:22.000Z - 6 months ago

Werewolf Therapeutics price target lowered to $7 from $8 at BofA

2025-11-07T14:15:14.000Z - 6 months ago

Werewolf Therapeutics presents preclinical data on PREDATOR Platform

Nov 7, 2025, 9:00 AM EST - 6 months ago

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

2025-11-04T12:16:23.000Z - 6 months ago

Werewolf Therapeutics reports Q3 EPS (36c), consensus (38c)

Nov 4, 2025, 7:00 AM EST - 6 months ago

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-10-08T12:06:01.000Z - 7 months ago

Werewolf Therapeutics receives FTD from U.S. FDA for WTX-124

Oct 8, 2025, 8:00 AM EDT - 7 months ago

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Oct 3, 2025, 9:00 AM EDT - 7 months ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Sep 8, 2025, 2:00 PM EDT - 8 months ago

Werewolf Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

2025-08-25T11:10:16.000Z - 9 months ago

Werewolf Therapeutics price target lowered to $8 from $9 at BofA

2025-08-21T09:45:12.000Z - 9 months ago

Werewolf Therapeutics price target lowered to $3 from $4 at Citizens JMP

Aug 14, 2025, 7:00 AM EDT - 9 months ago

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 9, 2025, 8:00 AM EDT - 10 months ago

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

Jun 12, 2025, 8:00 AM EDT - 11 months ago

Werewolf Therapeutics to Participate in the BIO International Convention

May 29, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 1 year ago

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 14, 2025, 6:15 PM EDT - 1 year ago

Werewolf Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

May 8, 2025, 10:00 AM EDT - 1 year ago

Werewolf Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:05 AM EDT - 1 year ago

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

May 5, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Apr 7, 2025, 1:30 PM EDT - 1 year ago

Werewolf Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 11, 2025, 11:20 AM EDT - 1 year ago

Werewolf Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Feb 24, 2025, 7:30 AM EST - 1 year ago

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Jan 13, 2025, 8:00 AM EST - 1 year ago

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Dec 5, 2024, 12:30 PM EST - 1 year ago

Werewolf Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 20, 2024, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 7, 2024, 9:02 AM EST - 1 year ago

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 25, 2024, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Transcript: Study Update

Jun 1, 2024, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

May 30, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 23, 2024, 5:00 PM EDT - 2 years ago

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

May 3, 2024, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 10:05 AM EDT - 2 years ago

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 2 years ago

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Apr 4, 2024, 4:30 PM EDT - 2 years ago

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Mar 7, 2024, 7:00 AM EST - 2 years ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 8:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Jan 8, 2024, 7:00 AM EST - 2 years ago

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Jan 4, 2024, 4:05 PM EST - 2 years ago

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Nov 22, 2023, 7:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:25 PM EST - 2 years ago

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 3, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 31, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 11, 2023, 4:05 PM EDT - 2 years ago

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Aug 10, 2023, 7:10 AM EDT - 2 years ago

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 7:00 AM EDT - 3 years ago

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

longshot45 May. 12 at 7:26 PM

0 · Reply

BiotechValues May. 12 at 2:06 PM

$HOWL to me this suggests they have another announcement coming in the near-term, or why not just give cash guidance with the 10q update?

2 · Reply

longshot45 May. 12 at 1:52 PM

$HOWL Vanguard new major buyer here as Luke and Ansbert continue their dumping. Was wondering who was helping to absorb their destructive actions

0 · Reply

BiotechValues May. 9 at 3:28 PM

1 · Reply

BiotechValues May. 9 at 2:59 PM

2 · Reply

longshot45 May. 7 at 10:31 PM

2 · Reply

longshot45 May. 7 at 6:08 PM

$HOWL MPM stop monkeying around and Just break .62 already. All this hundreth of a penny BS is such a waste of time for no more than a buck difference. Cant wait for Luke and Ansberth to be gone

2 · Reply

OfficialStocktwitsUser May. 6 at 2:43 AM

0 · Reply

GregK13 May. 5 at 11:30 PM

$HOWL schedule 13 D form just filed who’s investing in the company?

1 · Reply

zawojak May. 5 at 6:48 AM

$HOWL why is Luke disposing his shares ?

1 · Reply

GangsterX May. 1 at 4:16 PM

$ATYR $HOWL still holding but small position

0 · Reply

GWaldorf5040 Apr. 28 at 3:20 PM

$HOWL Thinking of buying back the dip… I’ll wait a little bit

1 · Reply

zawojak Apr. 28 at 1:57 PM

$HOWL as I said most liekly this is now done. Pink sheets soon. IMHO

0 · Reply

GangsterX Apr. 28 at 1:53 PM

$HOWL Filled .77... Medium size ding dong. how about that baby???? U like that ??

0 · Reply

longshot45 Apr. 28 at 1:40 PM

$HOWL Just great MPM just filed to sell more of its stake. Luke and Ansbert both suck

0 · Reply

longshot45 Apr. 27 at 3:21 PM

$HOWL Someone is pumping this early; were over a week out from ER. Maybe I wont be able to add more under .8

0 · Reply

GangsterX Apr. 24 at 9:02 PM

$HOWL thinking to get in this one next week under .81.

1 · Reply

GWaldorf5040 Apr. 13 at 1:43 PM

$HOWL nice flip I just sold :D buy low sell high mf 🤗

1 · Reply

GWaldorf5040 Apr. 10 at 5:13 PM

$HOWL added more

0 · Reply

Lima2111 Apr. 9 at 9:55 PM

$HOWL anyone who’s looked into this deeper can help with your view on potential outcome. I see Lynx upped its shares and is known for catalyst strat alt plays for biotechs. At the same time stock trades at net cash with 32M market cap, while 57M cash and 28M debts. But Jazz milestone payment in future of 1.2B for WTX - but not de risked yet as early stage and also lower NPV in a price valuation. Plus 2 additional assets in Phase 1. I can see a potential 2-3X if things go well, but since market overcrowded and all early stage with high failure rate still, it may likely be 1.5… but then how deep can it fall if it already trades at cash? Views appreciated!

2 · Reply

zawojak Apr. 9 at 7:27 PM

$HOWL bad news coming I suppose.

0 · Reply

LabPsycho Apr. 6 at 5:30 PM

$HOWL Note the skill in predicting this 35% price move and target price perfectly.

2 · Reply

Market Cap	32.10M
Revenue (ttm)	0.00
Net Income (ttm)	-60.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	561,700
Avg Vol	402,190
Day's Range	N/A - N/A
Shares Out	48.60M
Stochastic %K	13%
Beta	0.41
Analysts	Strong Sell
Price Target	$6.00